sorafenib has been researched along with Triple Negative Breast Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CT; Chiu, TY; Fang, MY; Hsu, CY; Hsu, TA; Huang, LR; Huang, YC; Liu, KL; Liu, YT; Lo, CF; Pan, PY; Tsou, LK; Yeh, TK | 1 |
| Huang, LL; Jiang, HL; Liu, DM; Wan, X; Wang, Y; Xing, L; Zhang, MM; Zhou, TJ | 1 |
| Gao, G; Huang, Z; Li, L; Luo, C; Mao, Y; Qi, W; Wang, G; Yang, X; Yang, Z; Zhou, T; Zhu, L | 1 |
| Booth, L; Bose, P; Dent, P; Geyer, CE; Gordon, S; Kmieciak, M; Massey, HD; McGuire, WP; Moran, RG; Poklepovic, A; Quigley, M; Roberts, JD; Shafer, DA; Shrader, E; Strickler, K; Tombes, MB; Wan, W | 1 |
| Chen, KF; Chu, PY; Huang, CT; Huang, TT; Lau, KY; Lee, CH; Liu, CY; Shiau, CW; Su, JC; Tsai, WC; Tseng, LM; Wang, WL; Yang, HP | 1 |
1 trial(s) available for sorafenib and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Phase I study of pemetrexed with sorafenib in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Female; Humans; Inflammation; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Pemetrexed; Phenylurea Compounds; PTEN Phosphohydrolase; Sorafenib; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
4 other study(ies) available for sorafenib and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Targeting the Phosphatidylserine-Immune Checkpoint with a Small-Molecule Maytansinoid Conjugate.
Topics: Humans; Ligands; Phosphatidylserines; RNA, Messenger; Sorafenib; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2022 |
Tumor microenvironment-initiated lipid redox cycling for efficient triple-negative breast cancer therapy.
Topics: Cell Line, Tumor; Humans; Hydrogen Peroxide; Iron; Lipid Peroxides; Nanoparticles; Oxidation-Reduction; Reactive Oxygen Species; Sorafenib; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2023 |
Stem-like tumor cells involved in heterogeneous vasculogenesis in breast cancer.
Topics: Actins; Aldehyde Dehydrogenase 1 Family; Angiogenesis Inhibitors; Animals; Cell Differentiation; Cell Line, Tumor; Endothelial Cells; Eye Proteins; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Neovascularization, Pathologic; Nerve Growth Factors; Serpins; Sorafenib; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Humans; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Taxoids; Triple Negative Breast Neoplasms | 2017 |